Depressant effects of Agastache mexicana methanol extract and one of major metabolites tilianin  by González-Trujano, María Eva et al.
185Asian Pacific Journal of Tropical Medicine (2015)185-190
Document heading          doi: 10.1016/S1995-7645(14)60312-6 
Depressant effects of Agastache mexicana methanol extract and one of 
major metabolites tilianin
María Eva González-Trujano1, Hilda Ponce-Muñoz2, Sergio Hidalgo-Figueroa2, Gabriel 
Navarrete-Vázquez2, Samuel Estrada-Soto2*
1Laboratorio de Neurofarmacología de Productos Naturales de la Dirección de Investigaciones en Neurociencias. Instituto Nacional de Psiquiatr侏a 
“Ramón de la Fuente Muñiz”, México, D.F.14370, México
2Facultad de Farmacia, Universidad Autónoma del Estado de Morelos, Cuernavaca, Morelos, México
 Contents lists available at ScienceDirect
Asian Pacific Journal of Tropical Medicine
journal homepage:www.elsevier.com/locate/apjtm
ARTICLE INFO                           ABSTRACT
Article history:
Received 26 December 2014
Received in revised form 10 January 2015
Accepted 22 February 2015
Available online 20 March 2015
Keywords:
Agastache mexicana
Anxiety
Benzodiazepine
Central nervous system
Sedative
Tilianin
  *Corresponding author: Dr. Samuel Estrada-Soto, Facultad de Farmacia, 
Universidad Autónoma del Estado de Morelos, Avenida Universidad 1001, Colonia 
Chamilpa, C.P. 62209. Cuernavaca, Morelos, México. 
     Tel/Fax: +52 777 329 7089
     E-mail: enoch@uaem.mx
   Foundation project: This work was partially supported by CONACYT 80811, 
NC12.3280 grant and Faculty of Pharmacy Budgets (FECES 2011 and 2012).
1. Introduction
  Agastache mexicana (A. mexicana) is a native herb from the Asian 
and North American regions[1,2]. In Mexico, it is commonly called 
“toronjil” and due to its large demand, it is cultivated in various 
regions such as Mexico City and the states of Hidalgo, Mexico, 
Morelos, Puebla and Veracruz. It is used to treat anxiety, insomnia 
and cardiovascular disorders, as well as rheumatism, stomach pain, 
and gastrointestinal affections[3-6]. Inflorescences are preferred to 
alleviate pain and aerial parts to produce sedative activity[7].
  Pharmacological properties such as anxiogenic[8] or anxiolytic-
like[9] behaviors, vasorelaxant[10], antioxidant[11], antinociceptive 
and anti-inflammatory effects[12] have been recently showed in 
extracts from A. mexicana. It has also been reported the presence 
of flavonoids as the main secondary metabolites that characterize 
the Mexican species of Agastache genus[13]. However, scientific 
studies have not been undertaken to identify some active 
metabolite and the possible involved mechanism of action for 
Objective: To determine the depressant-like effects and the possible mechanism of action 
of tilianin isolated from active methanol extract of Agastache mexicana (A. mexicana). Also, 
to establish the pharmacophoric requirements of tilianin, as a possible ligand of GABAA/
BZD receptor, by the alignment of diazepam, CGS-9896 and diindole, using a previously 
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po.) and methanol crude extract (10 to 300 mg/kg, ip. and 300 mg/kg po.) from A. mexicana 
were evaluated for potential sedative and anxiolytic-like response drugs by using open-field, 
hole-board, cylinder of exploration, plus-maze and sodium pentobarbital-induced hypnosis 
mice methods. Results: Methanol extract and tilianin showed anxiolytic-like activity from 
a dosage of 30 mg/kg, ip. or 300 mg/kg, po. and were less potent than diazepam 0.1 mg/kg, 
a reference anxiolytic drug used. Moreover, depressant activity of both potentiates sodium 
pentobarbital (SP)-induced sleeping time. The anxiolytic-like effect of 30 mg/kg ip. observed 
for the extract and tilianin, by using the plus-maze model, was partially prevented in the 
presence of flumazenil (a GABAA/BZD antagonist, 5 mg/kg ip.) but not in the presence of WAY 
100635 (a selective 5-HT1A receptor antagonist, 0.32 mg/kg, ip.). Pharmacophoric modeling 
alignments of three agonist of GABAA/BZD allow identify seven chemical features. Tilianin 
contains six of the seven features previously determined. Conclusions: Results indicate 
that tilianin is one of the bioactive metabolites in the anxiolytic-like activity of A. mexicana, 
reinforcing its central nervous system uses, where GABAA/BZD, but not 5-HT1A, receptors are 
partially involved.
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the tranquilizing activity of A. mexicana. In the present study, 
systemic administration (intraperitoneal and esophagi) of a polar 
extract and the compound tilianin were evaluated in different 
experimental models in order to analyze its sedative and/or 
anxiolytic-like responses and to know the tilianin’s mechanism of 
action.
2. Materials and methods 
2.1. Plant material, extraction and isolation of tilianin
  A. mexicana (Kunth) E.F. Linton & Epling (toronjil) was collected 
in September 2008 in Morelos State, Mexico, and identified by Dr. 
Patricia Castillo-España. A voucher specimen (26336) was deposited 
at the HUMO-Herbarium of the Centro de Estudios Ambientales e 
Investigación “Sierra de Huautla” (CEAMISH) of the Universidad 
Autónoma del Estado de Morelos, México. Briefly, plant material 
was dried at room temperature (22 曟) and subjected to successive 
macerations with hexane, dichloromethane and methanol (3 
times for 72 h at room temperature). After filtration, extracts were 
concentrated in vacuo at 40 曟. Tilianin (Figure 1) was obtained by 
precipitation from liquid methanol extract adding ethyl acetate[10]. 
Purity of tilianin (>95%) was confirmed by HPLC method 
previously developed[14] (Supporting information).
Figure 1. Tilianin chemical structure.
2.2. Drugs 
  All pure compounds were purchased from Sigma-Aldrich Co. 
Sodium pentobarbital, WAY-100635, tilianin and methanol extract 
were dissolved in saline solution (s.s.); flumazenil (GABAA/
BZD receptor antagonist) and diazepam (reference drug) were 
resuspended in the vehicle (0.2% tween 80 in s.s.). All drugs and 
the extract were freshly prepared the day of the experiments and 
administered via esophagi (po.) and/or intraperitoneal (ip.) in a 
volume of 10 mL/kg body weight. Control animals received the 
same volume of the vehicle and in the same route of administration.
2.3. Animals
  Male Swiss albino mice (25-30 g, Instituto Nacional de Psiquiatría 
Ramón de la Fuente Muñíz) were used in pharmacological tests. 
The animals were kept at constant room temperature [(22依1) 曟] and 
maintained in a 12 h/12 h light/dark cycle. Experiments were carried 
out in accordance with the Ethical Committee Guidelines laid down 
by the local committee regarding the care and use of animals for 
experimental procedures. The animals were fed ad libitum with 
standard food and water during the course of the study.
2.4. Pharmacological evaluations
  All mice were adapted to manipulation through a daily s.s. 
injection or esophagi administration for 5 days before the treatments 
were administered. Anxiolytic or sedative-like effects of several 
dosages of the methanol extract (10, 30, 100 and 300 mg/kg, ip. or 
300 mg/kg po.) and tilianin (30, 100 and 300 mg/kg, ip. or 300 mg/
kg, po.) were compared to that obtained with the reference anxiolytic 
drug diazepam ED50=0.1 mg/kg (as previously determined)[15]. For 
analyzing mechanism of action, administration of the GABAA/BZD 
receptor antagonist (flumazenil, 5 mg/kg, ip.) or 5-HT1A antagonist 
(WAY100635, 0.32 mg/kg, ip.) was done 15 min before treatment. 
For each experimental procedure, animal groups consisted of at least 
6 mice. The extract and pure compounds (tilianin or diazepam) were 
evaluated 60 min and 30 min after administration, respectively, as 
follows:
2.4.1. Open-field  
  Sixty minutes after the administration of the extract or tilianin 
and 30 min after diazepam (previous to the anti-anxiety tests), each 
mouse was placed into a cage divided in 12 squares (4 cm 伊 4 cm). 
The number of squares explored by each mouse in a 2 min interval 
was registered as ambulatory activity.
2.4.2. Hole board test
  Mice were individually placed in the centre of a perforated board 
and the number of head-dips was registered during a 3 min trial. The 
perforated board test was made by using a plastic floorboard, 40 cm
伊40 cm伊25 cm, in which 16 evenly spaced holes (3 cm in diameter) 
were made; the board was delimited by a glass box having 30 cm 
in height[16]. The number of explored holes provides a measure of 
the number of head-dips. Reduced number of head-dips reveals an 
anxiolytic-like effect.
2.4.3. Exploratory rearings
  Each mouse was individually placed on a filter paper-covered floor 
of a glass cylinder (16 cm in height, 11 cm in diameter). The number 
of spontaneous rearings on its posterior limbs is counted during the 
first 5 min. Reduced exploratory rearing showed by naive mice after 
placement in an unfamiliar environment reveals a sedative effect[17]. 
Control animals received vehicle.  Diazepam was used as positive 
control in all the tests.
2.4.4. Elevated plus-maze
  The method used in this study was modified from Lister (1987)[18]. 
The apparatus consists of two open arms (25 cm伊 5 cm), facing each 
other, and two closed arms (25 cm伊5 cm伊15 cm) with an open roof 
and walls having 40 cm in height. Mice were placed individually 
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onto the centre of the apparatus facing an open arm, and the time 
spent on and entries onto each arm were noted for 5 min by a trained 
observer who remained unaware of the treatments. The maze was 
wiped clean with water and dried after each trial. An arm entry 
was recorded when all four paws of the mouse were in the arm: the 
total time spent in open-sided arms provides a measure of general 
anxiolytic activity.
2.4.5. Sodium pentobarbital-induced hypnosis
  For this test, mice received 42 mg/kg, ip. of sodium pentobarbital. 
Each mouse was observed for the onset of uncoordinated movements 
(sedative phase) and the loss of righting reflex (hypnosis), but also 
for duration of sleep (the criterion for sleep is defined as the loss of 
righting reflex). The time between loss and recovery of the righting 
reflex was recorded as sleeping time[19].
2.5. Pharmacophore modeling of tilianin on GABAA/BZD 
receptor
  Tilianin was analyzed as a possible ligand of GABAA/BZD receptor 
using a previously described pharmacophoric model generated from 
the alignment of diazepam, CGS-9896 and diindole, three well-
known GABAA-BZD receptor agonists[20]. The pharmacophore 
analysis was generated using Discovery Studio (version 3.5, 
Accelrys, Inc. San Diego).
2.6. Statistical analysis
  Results are expressed as mean依SEM. Statistical differences were 
analyzed using a one-way analysis of variance (ANOVA) followed 
by Dunnett´s test. A value of P < 0.05 was considered significant. A 
SIGMA STAT® version 2.3 software program was used.
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Figure 2.  Anxiolytic-like-effects of a crude methanol extract (10 to 300 mg/kg, ip.), tilianin (30 to 300 mg/kg, ip.) and diazepam (DZP, 0.1 mg/kg ip.) on 
the ambulatory activity (A), in the hole-board (B) and the rearing cylinder (C) tests. 
ANOVA followed by Dunnett’s test, *P<0.001 significantly different from the vehicle group. 
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Figure 3.  Dose-response effect of a crude methanol extract (10 to 300 mg/kg, ip.) and tilianin (30 to 300 mg/kg, ip.) on the latency to the motor 
incoordination (A, sedative); loss of righting reflex (B, hypnosis) and sleeping time (C) induced by sodium pentobarbital (42 mg/kg). 
ANOVA followed by Dunnett’s test: *P<0.05 significantly different from the vehicle group.
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3. Results
  In the experimental models, methanol extract and tilianin did not 
modify the ambulatory activity of mice when tested in the open-field 
test (Figure 2A). In contrast, the extract and the active metabolite 
tilianin induced a significant reduction in the number of head-dips 
from the 30 mg/kg dosage ip. and 300 mg/kg po. (Figure 2B), this 
effect was observed in a dose-dependent manner in both cases. In 
a similar manner, a significant diminution in the rearing behavior 
was observed in mice treated with the extract and tilianin (Figure 
2C). These significant anti-anxiety responses resembled the effect 
observed with diazepam at 0.1 mg/kg (Figure 2).
  As shown in Figure 3, the methanol extract of A.mexicana aerial 
parts and tilianin did not modify the latency to the onset of sedation 
and hypnosis induced by sodium pentobarbital (Figure 3A and 
3B), however the sleeping time was significantly increased in mice 
receiving 30, 100 and 300 mg/kg ip. and 300 mg/kg po., respectively, 
of both test samples (Figure 3C). Finally, in order to corroborate the 
anxiolytic-like effect of test samples, plus-maze model were used. 
Thus, both extract and tilianin induced significant anxiolytic effect at 
30 mg/kg ip. and 300 mg/kg po., compared to control group (Figure 
4). Also, it was evaluated the anxiolytic-like effect of the flavonoid 
tilianin in the presence of flumazenil (a GABAA/BZD antagonist, 
5 mg/kg, ip.) and WAY100635 (a 5-HT1A receptor antagonist, 0.32 
mg/kg, ip.) in the elevated plus-maze model. As observed in Figure 
4, anxiolytic-like response of tilianin is prevented in the presence 
of flumazenil but not in the presence of WAY100635, suggesting a 
GABAergic involvement.
  On the other hand, tilianin was analyzed as a possible ligand of 
GABAA/BZD receptor using a previously described pharmacophoric 
model[20]. Pharmacophore modeling was performed by alignment 
of diazepam, CGS-9896 and diindole, three GABAA/BZD receptor 
agonists (Figure 5A). This model contains seven chemical features: 
four hydrophobic sites H1-H4 (cyan color), two hydrogen bond 
acceptors A1 and A2 (green color) and a donor of hydrogen bonds 
D1 (magenta color). According to the analysis of the structural 
requirements in the pharmacophoric model for GABAA/BZD 
receptor agonists, we found that tilianin contains six of the seven 
chemical features (Figure 5B). The gray sphere (H3, Figure 5B) 
represents a feature not found in the pharmacophore mapping with 
tilianin. However, this hydrophobic fragment belongs exclusively to 
diazepam structure (Figure 5C) and it was not common between the 
other two compared GABAA/BZD receptors agonists.
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Figure 4. Anxiolytic-like-effects expressed as the time spend in open-sided 
arms of a crude methanol extract and tilianin (30 mg/kg, ip. and 300 mg/kg, 
po.) in comparison to diazepam (DZP, 0.1 mg/kg ip.). 
Tilianin 30 mg/kg, ip. in the presence of flumazenil (5 mg/kg, a GABAA/
BZD antagonist) and WAY100635 (0.32 mg/kg, a 5-HT1A receptor). 
ANOVA followed by Dunnett’s test, *P<0.001 significantly different from 
the vehicle group. 
4. Discussion
  In the present study, it was investigated the anxiolytic-like activity 
of a polar extract obtained from the A. mexicana aerial parts and one 
of its major active metabolites identified as tilianin, from which it 
was also explored the feasible mechanism of action.
  A. mexicana is popular in markets of Mexico because of its use 
as a tranquilizer. As a medicinal remedy, it is common that both all 
A B C
Figure 5. (A) The superimposition of 7 chemical features pharmacophore model with diazepam (yellow), CGS-9896 (cyan), and diindole (green)[20]. 
(B) The pharmacophore mapping analysis of Tilianin.
(C) The pharmacophore mapping analysis of diazepam[20]. 
H1-H4 (cyan color) represent hydrophobic region, A1 and A2 (green color) represent a hydrogen bond acceptor, and D1 (magenta color) represents a 
hydrogen bond donor.
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the aerial parts and only the flowers, fresh or dried, are prepared in 
boiling water as an infusion or decoction or even as maceration in 
ethanol to treat anxiety and insomnia[3,4]. In our study, a methanol 
extract of aerial parts of A. mexicana produced a tranquilizer effect 
that was not associated to sedative-like response as observed in 
the open-field test in mice. These results were resembled with 
an active metabolite that was identified as tilianin obtained as a 
white-yellowish amorphous solid by spontaneously precipitation 
of the methanol extract of A. mexicana. The spectroscopic and 
spectrometric data (IR, NMR 1H, 13C and GC-MS) of this metabolite 
were compared with values previously reported[10].
  The tranquilizer effect of the extract and tilianin was observed as 
a significant decrease in the rearing and head-dipping behaviors. 
These results are in agreement to a recent report that demonstrates 
anxiolytic-like response in both A. mexicana subspecies mexicana 
and xolocotziana aerial parts by administration of an aqueous 
extract at doses of 0.1 to 10 mg/kg, suggesting that over 10 mg/kg
is possible to induce sedation and locomotor activity diminution 
because of a general inhibition in the central nervous system[9]. 
In our study, the methanol extract and tilianin did not modify the 
latency to the onset of sedation and hypnosis induced by sodium 
pentobarbital, however, the sleeping time was significantly increased 
in mice receiving extract or tilianin. The synergism in the depressant 
response was observed in a dose-dependent manner, being more 
effective in the presence of the extract, suggesting that more than 
one compound is involved in the extract effect even though tilianin. 
It is important to mention that several flavonoids have been reported 
into the aqueous and organic extracts of A. mexicana aerial parts[9,13], 
which might generate synergism to produce depressant activity. This 
fact also might explain why lower dosage of the aqueous extract 
produced major sedative-like response than the alcoholic extract. 
Moreover, it has been described that some flavonoids might not 
produce anxiolysis[21]; but they may modulate motor movements 
and locomotion[22]. Besides, it had been reported that lower dosage 
(3, 9 and 12 mg/kg, ip.) of A. mexicana did not produce sedative 
effect; on the contrary it induced an anxiogenic-like reponse instead 
of anxiolytic- by using elevated plus-maze rat model[8]. In that 
report, authors used an aqueous extract prepared from the leaves of 
A. mexicana; however, it has been described that aerial parts or even 
inflorescences are preferred to produce tranquilizing activity[3,4,7]. 
In our study, the elevated plus-maze model was used to corroborate 
the anxiolytic-like action of the methanol extract of the A. mexicana 
aerial parts and its metabolite tilianin as a real alternative for the 
treatment of depressive issues. In this context, diazepam is a well-
known benzodiazepine used as reference drug; it is a GABAergic 
agonist and the most widely prescribed class of psychoactive drugs 
for anxiety, despite the important unwanted side-effects that they 
produce such as sedation, myorelaxation, ataxia, amnesia, ethanol 
and barbiturate potentiation and tolerance[23].
  Pharmacological studies have reported that the presence of 
flavonoids, as major components in polar extracts of A. mexicana 
species, is responsible for the pharmacological properties found 
among tilianin[9,10,13,14,24]. Although it was described the total 
flavonoids contents in organic[13]  and aqueous extracts of A. 
mexicana by an HPLC method[9], it has not been found the possible 
compound(s) responsible for the CNS effects and its mode of 
action. Also, in neither of them was reported the presence of 
tilianin[8,9,13]. In this framework, we evaluated the anxiolytic-like 
effect of the flavonoid tilianin, as one of the major constituents in
A. mexicana, in the presence of flumazenil (a GABAA/BZD 
antagonist) and WAY100635 (a 5-HT1A receptor antagonist). Since 
anxiolytic-like response of tilianin is prevented in the presence of 
flumazenil but not in the presence of WAY100635 suggested that 
a GABAergic system is involving in its mode of action. It is well 
known that some flavonoids isolated from plants used as tranquilizers 
in folk medicine have shown to possess a selective and relatively 
mild affinity for GABAA/BZD receptors and a pharmacological 
profile compatible with a partial agonistic action[20,25-28]. Tilianin 
was analyzed as a possible ligand of GABAA/BZD receptor using 
a previously described pharmacophoric model[20]. Pharmacophore 
modeling was performed by alignment of diazepam, CGS-9896 
and diindole, three GABAA/BZD receptor agonists. According to 
the analysis of the structural requirements in the pharmacophoric 
model for GABAA/BZD receptor agonists, we found that tilianin 
contains six of the seven chemical features: H1, H2 and H4 (cyan 
color), two hydrogen bond acceptors A1 and A2 (green color) and 
a donor of hydrogen bonds D1 (magenta color). The gray sphere 
(H3, Figure 5B) represents a feature not found in the pharmacophore 
mapping with tilianin. However, this hydrophobic fragment belongs 
exclusively to diazepam structure and it was not common between 
the other two compared GABAA/BZD receptors agonists. This 
pharmacophore analysis could be a reasonable qualitative prediction 
of binding of the spatial arrangement of these six chemical features. 
Last results reinforce the participation of GABAergic system in 
anxiolytic-like activity of tilianin. 
  Chemical entities with new or known therapeutic targets are 
needed to control anxiety more effectively, with less adverse 
effects and having a neutral impact on known cardiovascular risk 
factors. Bioactive compounds from medicinal plants are one of the 
alternatives for the discovery and development of new agents for 
the treatment of anxiety and related diseases[28]. Thus, flavonoids 
represent serious candidates for the detection of hits or leads with 
potential uses in therapeutics due to their beneficial properties 
in cardiovascular disease among their pharmacological effects 
as anti-inflammatory, antioxidant, antiviral, neuroprotector and 
anticarcinogenic agents[29].
  In conclusion, current results give evidence that tilianin is one of 
the bioactive compounds responsible for the central nervous activity 
of A. mexicana as anxiolytic agent, suggesting the GABAA/BZDs, 
but not 5-HT1A, receptor involvement.
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